Table 1 Association between clinical factors and HLA class I expression in 212 breast cancer patients
From: Clinical implication of HLA class I expression in breast cancer
| Â | Positive (n = 69) | Negative (n = 143) | p value |
|---|---|---|---|
Age (years) | Â | Â | Â |
< 50 | 23 (11%) | 59 (28%) | 0.2669 |
51 < | 46 (22%) | 84 (40%) | Â |
Tumor size | Â | Â | Â |
T1 | 35 (17%) | 51 (24%) | 0.0641 |
T2 | 31 (15%) | 72 (34%) | Â |
T3 | 1 | 12 (57%) | Â |
T4 | 2 | 8 (4%) | Â |
Nodal invasion | Â | Â | Â |
Negative | 49 (23%) | 79 (37%) | 0.0278 |
Positive | 20 (9%) | 64 (30%) | Â |
Estrogen receptor | Â | Â | Â |
Negative | 18 (8%) | 53 (25%) | 0.1126 |
Positive | 51 (24%) | 90 (42%) | Â |
Progesterone receptor | Â | Â | Â |
Negative | 25 (12%) | 64 (30%) | 0.2387 |
Positive | 44 (21%) | 79 (37%) | Â |
Lymphatic invasion | Â | Â | Â |
Negative | 46 (22%) | 67 (32%) | 0.0067 |
Positive | 23 (11%) | 76 (36%) | Â |
Venous invation | Â | Â | Â |
Negative | 66 (31%) | 122 (58%) | 0.0260 |
Positive | 3 (1%) | 21 (10%) | Â |
TNM | Â | Â | Â |
I | 31 (15%) | 39 (18%) | 0.0110 |
II | 31 (15%) | 70 (33%) | Â |
III | 7 (3%) | 34 (16%) | Â |
Histology | Â | Â | Â |
IDC | 67 (32%) | 142 (67%) | 0.2040 |
ILC | 2 | 1 | Â |
HER2 receptor | Â | Â | Â |
Negative | 63 (30%) | 123 (58%) | 0.4539 |
Positive | 6 (3%) | 17 (8%) | Â |